⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 24, 2025

Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial

Janghee Woo Tingting Zhai Fang Yang Huilei Xu Margaret L. Healey Denise P. Yates Michael T. Beste David P. Steensma

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Clonal hematopoiesis mutations influence the incidence of at least one malignancy in patients.
KEY EVIDENCE: Cumulative incidence data were analyzed based on different doses of canakinumab treatment.
APPROACH: The analysis involved stratifying treatment effects within the CANTOS randomized clinical trial framework.
SIGNIFICANCE: Understanding these relationships can guide future treatment strategies for cancer prevention.

Implication

Supplementary figure reveals cumulative incidence of malignancies by treatment and canakinumab dose in randomized clinical trial.

Abstract

Supplementary Figure S1 shows cumulative incidence of at least one malignancy by treatment, stratified by the canakinumab dose.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Woo et al. (2025) studied this question.

synapsesocial.com/papers/689a0627e6551bb0af8ce0ec https://doi.org/10.1158/1940-6207.29636074

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025
2Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
3Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
4Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025
5Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2025

Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024
Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial2024